Results 11 to 20 of about 3,185 (155)
Background Mepolizumab and benralizumab are biologics approved for severe eosinophilic asthma. Mepolizumab is an anti-interlukin-5 (IL-5) antibody while benralizumab is an anti-interleukin-5 receptor alpha (IL-5Rα) antibody targeting the IL-5 receptor on
Arian Ghassemian +3 more
doaj +1 more source
Background and aims: Biologics that target Type 2 inflammation are effective in reducing exacerbations of severe asthma. We conducted a systematic review and integrated analysis of the efficacy and safety of these biologics in chronic obstructive ...
Hiroshi Ohnishi +2 more
doaj +1 more source
Background Benralizumab, an anti-interleukin-5 (IL-5) receptor α monoclonal antibody, significantly reduces the number of annual exacerbations and oral corticosteroid (OCS) maintenance doses for patients with severe eosinophilic asthma (SEA).
Takanori Numata +10 more
doaj +1 more source
Antagonism of cytokine-induced eosinophil accumulation in asthma [PDF]
Peer reviewedPublisher ...
Walsh, Garry M.
core +2 more sources
We described three severe asthmatics whose asthma symptoms were rapidly improved by benralizumab following favorable response to mepolizumab. Benralizumab-induced eosinophil depletion contributed to clinical improvement of severe asthma after mepolizumab-
Osamu Matsuno, Seijiro Minamoto
doaj +1 more source
Monoclonal antibodies in type 2 asthma : a systematic review and network meta-analysis [PDF]
Since novel treatments to target eosinophilic inflammation in Type 2 asthma are emerging, we aimed to evaluate and meta-analyze the efficacy of monoclonal antibodies to reduce exacerbation rate.
De Feyter, Silke +4 more
core +1 more source
Eosinophilic cystitis refractory to steroids successfully treated with benralizumab: A case report
We report a case of a 66-year-old male diagnosed with refractory to oral corticosteroids eosinophilic cystitis (EoC). Hematuria was the first and only sign of the disease that was otherwise asymptomatic, and the only abnormal lab finding he had was ...
George N. Konstantinou +1 more
doaj +1 more source
Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population [PDF]
Acknowledgments The authors thank Derek Skinner (Cambridge Research Support Ltd, Oakington, Cambridge, UK) for assistance with data extraction.Peer reviewedPublisher ...
Gibson, Danny +6 more
core +1 more source
PurposeTo characterize the clinical phenotypes of severe eosinophilic asthma based on early responsiveness to benralizumab in terms of forced expiratory volume in 1 second (FEV1) improvement.Patients and methodsSixty-four participants diagnosed with ...
Hideyasu Yamada +10 more
doaj +1 more source
Eosinophil Apoptosis and Clearance in Asthma [PDF]
Peer reviewedPublisher ...
Bickham U.R. +9 more
core +3 more sources

